To appraise the clinical and cost effectiveness of avelumab in combination with axitinib within its marketing authorisation for untreated advanced or metastatic renal cell carcinoma.
Status In progress
Process STA 2018
ID number 1547

Provisional Schedule

Expected publication 08 April 2020

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool


Companies sponsors Pfizer (avelumab, axitinib)
Others Department of Health and Social Care
  NHS Brighton & Hove CCG
  NHS England
  NHS Horsham and Mid Sussex CCG
  Welsh Government
Patient carer groups Black Health Agency
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Kidney Cancer Support Network
  Kidney Cancer UK
  Kidney Care UK
  Kidney Research UK
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  National Kidney Federation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  Association of Renal Technologists
  British Association of Urological Nurses
  British Association of Urological Surgeons
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Renal Society
  British Society of Urogenital Radiology
  British Uro-oncology Group
  Cancer Research UK
  Renal Association
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  Society for DGH Nephrologists
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society
  UK Renal Pharmacy Group
  Urology Foundation


Associated public health groups Public Health England
  Public Health Wales
Comparator companies EUSA Pharma (tivozanib)
  Ipsen (cabozantinib)
  Novartis (pazopanib)
  Pfizer (sunitinib)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Association of Renal Industries
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Kidney Patients Association
Relevant research groups Cochrane Kidney and Transplant Group
  Cochrane Urology
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
11 February 2020 Committee meeting: 2
15 January 2020 Committee meeting: 1
15 May 2019 Invitation to participate
05 February 2019 - 05 March 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
21 April 2017 In progress, DHSC Referral date received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance